China Intravenous Solutions Market Report 2022 to 2030

China Intravenous Solutions Market Analysis

$ 3999

China intravenous solutions market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The rise in the prevalence of malnutrition, the quicker turnaround and higher efficacy associated with intravenous solution therapy, and the rise in the geriatric population all contribute to the growth of the intravenous solutions market. The key players in this market are Fresenius Kabi AG, Pfizer, Inc., Otsuka Pharmaceutical Co., Ltd., Baxter, B. Braun Melsungen AG, Vifor Pharma Management Ltd., JW Life Science, Amanta Healthcare, ICU Medical Inc., Grifols, S.A.

ID: IN10CNPH318 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Aneri Parekh

Buy Now

China Intravenous Solutions Market Analysis Summary

China Intravenous Solutions Market is valued at around $674.9 Mn in 2022 and is projected to reach $1239.9 Mn by 2030, exhibiting a CAGR of 7.9% during the forecast period 2023-2030.

Intravenous therapy, sometimes known as IV therapy, is a medical practise that involves administering fluids, medications, and nutrients directly into a patient's vein. The intravenous route of administration is widely used to rehydrate or feed individuals with nutrients who, for various reasons, such as impaired mental capacity, cannot or do not wish to consume food or water orally. It may also be used to administer medication or other types of medical therapy, such as blood products or electrolytes, to correct electrolyte imbalances. The fastest approach to distribute pharmaceuticals and fluid replacement throughout the body is intravenously since this method introduces the drugs directly into the circulatory system, where they are promptly dispersed. Because of this, some recreational drugs are also taken via the intravenous mode of administration. Although they can also be given as a sustained infusion or drip, many therapies are given as a "bolus" or single dose. Only a qualified practitioner should execute the act of giving a therapy intravenously or setting up an intravenous line ("IV line") for future usage. The rise in the prevalence of malnutrition, the quicker turnaround and higher efficacy associated with intravenous solution therapy, and the rise in the geriatric population all contribute to the growth of the intravenous solutions market. The key players in this market are Fresenius Kabi AG, Pfizer, Inc., Otsuka Pharmaceutical Co., Ltd., Baxter, B. Braun Melsungen AG, Vifor Pharma Management Ltd., JW Life Science, Amanta Healthcare, ICU Medical Inc., Grifols, S.A.

Market Dynamics

Market Growth Drivers

The rise in neurological diseases and gastrointestinal disorders as a result of bad eating habits is one of the major reasons impacting the market's growth rate. The rise in healthcare spending is a major factor influencing the market for intravenous (IV) solutions. Rising infection rates and the growing acceptance of intravenous vitamin C treatments for colorectal cancer will both drive growth in the intravenous (IV) solution market. The actions of the government and increased public knowledge are two more factors that will favourably influence the market's rate of expansion. Another significant issue that will impede the growth of the market for intravenous (IV) solutions is the increase in diabetes and cancer incidence. Furthermore, a rise in sedentary behaviour and disposable income will accelerate market expansion.

Market Restraints

The market's ability to grow will be constrained by the product's high price, though. The regulatory authorities' stringent rules and growing technology regulations will further impede the growth of the intravenous (IV) solution industry. Lack of knowledge will further hinder the intravenous (IV) solution industry.

Competitive Landscape

Key Players

Fresenius Kabi AG
Pfizer, Inc.
Otsuka Pharmaceutical Co., Ltd.
Baxter
B. Braun Melsungen AG
Vifor Pharma Management Ltd.
JW Life Science
Amanta Healthcare
ICU Medical Inc.
Grifols, S.A.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

sexy Intravenous Solutions Market Segmentation

By Product Type

Total Parenteral Nutrition
Peripheral Parenteral Nutrition

By Nutrients Type

Carbohydrates
Vitamins and Minerals
Single Dose Amino Acids
Parenteral Lipid Emulsion
Others

By End Users

Hospitals
Specialty clinics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.